Biomolecular & Cell Technologies in the Netherlands

The Dutch government's vision reaches beyond lab discoveries. Biotechnology by design now anchors national strategy, embedding sustainable bioprocesses from molecule to market and placing responsibility on innovators to deliver health, food, and environmental solutions from day one. This strategy represented intentional ecosystem design rather than organic evolution. 

The Netherlands hosts interconnected biotech hubs, including Rotterdam's regenerative medtech initiatives, where Kite’s manufacturing facility serves 300+ European hospitals with cell therapy, which brings the strategy to life geographically.

The Dutch biotech narrative extends worldwide. The Netherlands is becoming a preferred destination for entrepreneurs, international researchers, and skilled professionals due to its supportive policies, collaborative networks, and pivotal role in Europe's life sciences economy. Their expertise and perspectives strengthen the ecosystem, creating pathways for anyone ready to drive meaningful change.

The Netherlands stands at the forefront of biomolecular and cell technologies, blending cutting-edge research with strategic investments to tackle global health and sustainability challenges. This sector drives innovation across health, agriculture, and industry, supported by world-class infrastructure and collaborative ecosystems such as Leiden Bio Science Park.

The biomolecular and cell technologies industry in the Netherlands focuses on developing, manufacturing, and applying biotechnological solutions using biological systems, biomolecules, and cellular processes. This field supports national resilience in health systems, food security, environmental goals, and economic independence, with the government viewing it as essential infrastructure. 

Leaders like Karen Vink illuminate the global draw. As Director of Public Affairs at Kite, she oversees external relations for their Amsterdam facility, scaled over seven years from startup to a European hub serving 300+ hospitals across 24 countries with CAR T-cell therapies and about 900 multinational employees. "Because cell therapy is an individualised treatment, it involves complex, time‑sensitive logistics as cells move back and forth throughout the process," Vink explains. "Schiphol Airport was therefore an important factor in our decision to establish operations here, thanks to its direct connections across Europe and frequent daily flights. Maintaining this level of connectivity will remain critical for the future." Vink highlights the ecosystem advantages, 

"As a country, we are highly skilled in general in the Netherlands and the proficiency of English is quite good here. It's a stable environment with a lot of networks in international schooling if you need to bring your family. These are all things that are in place in this country." 

Karen Vink, Director Public Affairs Kite 
 

This ecosystem supports diverse applications beyond cell therapy. Pioneering companies like Outlander Materials extend this impact into sustainability. Lori Goff, Founder and CEO, transforms waste into valuable materials, showcasing biotech's versatility. "It's an important space if we want to solve many challenges ahead across medical, materials, climate tech, health, and agricultural sectors ," she says. Biotechnology enables targeted, scalable solutions: engineering drought-resistant crops to slash pesticide and water use; precision medicine to reduce the approximately 200,000 deaths in Europe attributed to adverse drug reactions (ADRs) from properly prescribed medications due to individual metabolic differences; and efficient material development for climate goals. After costly R&D starts, it drives down expenses while boosting effectiveness over broad-spectrum alternatives.

This multi-sector approach complements the regulatory expertise gained from hosting the European Medicines Agency in Amsterdam since 2019, strengthening the country's role as a key regulatory centre for European biotech.

The Netherlands biotech market is experiencing rapid growth, rising from $7.32 billion in 2024 to a projected $52.33 billion by 2032 at a CAGR of 44.99% between 2025 and 2032. Within this growth, specific segments lead the expansion:

Projections indicate that the cell separation technology market will grow from $85.3 million in 2025 to $181.6 million by 2032 at an 11.5% CAGR. Biotechnology reagents will increase from $650 million in 2024 to $1.2 billion by 2032 at an 8.5% CAGR. White biotechnology rises from $1.45 billion in 2025 to $3.35 billion in 2032 at 12.0-13.5% CAGR.

The Life Sciences and Health (LSH) sector, spanning pharma, biotech, medtech, agri-food, and industrial applications, generates €7 billion in economic activity and €50 billion in exports, employing over 50,000 people across more than 2,000 companies. Dutch startups raised $3.5 billion in funding in 2024, including EV Biotech for industrial microbes and Hudson River for crop editing.

Genmab in Utrecht develops antibody therapeutics for immuno-oncology. Merus in Utrecht advances bispecific antibody treatments. Pharming Group in Leiden focuses on biologics, while uniQure in Amsterdam pioneered gene therapy for haemophilia B. Hudson River Biotechnology in Wageningen achieves CRISPR breakthroughs for crop regeneration. ProQR Therapeutics works on oligonucleotide therapies alongside EV Biotech's microbial platforms for industrial plastics and Outlander Materials' waste-to-bioplastic conversion, balancing medical innovation with agri/food and industrial applications. Experts like Thijs Remijn provide insight into talent strategies. Thijs Remijn, Project Leader for the Human Capital Agenda at Leiden Bio Science Park, offers a dual perspective from biomedical sciences and life science recruitment. After years of matching talent to South Holland's ecosystem, he now leads initiatives that inspire schoolchildren and attract international experts for the park's 27000+ workers. Based on his knowledge of the ecosystem and experience he shares his perspective on how firms approach rare disease treatments.

"While focusing on orphan diseases, some companies develop platform technologies that can be applied across multiple rare conditions,  transforming a single-disease focus into a scalable and commercially viable model."

Thijs Remijn, Project Leader Human Capital Agenda, Leiden Bio Science Park

Leiden Bio Science Park alone hosts over 230 Life Science &Health related companies, including a thriving start-up community and international companies such as Johnson & Jonson, Bristol Myers Squibbb,  Batavia Biosciences and many more. International firms, including Merck Sharp & Dohme (MSD), Genmab, Thermo Fisher Scientific, Biogen, and BIOMÉRIEUX, maintain major operations in the country.

Dutch research institutes drive cutting-edge biomolecular innovation: Hubrecht Institute pioneers organoid technology and stem cell biology, Bijvoet Centre excels in structural biology using NMR, X-ray crystallography, electron microscopy, and mass spectrometry, while Eindhoven University advances synthetic biology for DNA data storage and biomolecular computing. 

Entrepreneurs like Linda Dijkshoorn, Founder and Chief Commercial Officer of EV Biotech, a venture transforming microbes into biodegradable plastics, apply these advances commercially. 

"It's always easier to start with the technology and train yourself to become a good business person than the other way around," 

Linda Dijkshoorn, Founder & CCO EV Biotech
 

 After seven years navigating investor challenges, "It's a lot harder to absorb a technology later on if you don't have the student schedule where you still have time to educate yourself." Regional clusters amplify these breakthroughs: Utrecht Science Park focuses on biomolecular research and organoids, Leiden Bio Science Park drives biopharmaceuticals, Pivot Park Oss specialises in small molecules, Amsterdam Science Park supports EMA regulatory work, while Groningen and High Tech Campus Eindhoven target advanced materials. Key advances span personalised medicine, gene therapy, diagnostics, and automated lab processes. These innovations thrive within supportive regulatory frameworks.

The national framework includes the Genetically Modified Organisms Decree, Order, Bureau GGO for authorisations, and COGEM for risk assessments. The EMA in Amsterdam evaluates products for 450 million EU citizens, enhancing the country's regulatory expertise since 2019. This regulatory strength directly benefits companies, which rely on fast and predictable approval pathways for advanced cell therapies distributed across Europe.

Lori Goff of Outlander Materials highlights how these supportive policies extend to local levels. "The individual regions and municipalities are easy to talk with,helpful and  looking for solutions," she notes. 

"Gemeente Rotterdam, I think, is one of the most supportive in the Netherlands... all of these groups are very approachable and  willing to work with emerging and novel concepts."

Lori Goff, Founder Outlander Materials
 

Regulatory sandboxes create flexible testing zones for new technologies, speeding lab-to-market transitions while ensuring safety. Startups like Outlander Materials employ these sandboxes to test novel biomolecular materials in controlled regulatory environments, reducing early-stage commercial risk while accelerating innovation. The Netherlands advocates for EU-wide harmonised rules through initiatives such as the EU Biotech Act to encourage innovation while maintaining scientific standards.

The government commits €1.3 billion through the National Growth Fund between 2025 and 2040, with €338 million for Biobased Circular, €325 million for Oncode Accelerator, €246 million for Biotech Booster, €124.5 million for animal-free research, and €56.3 million for RegMed XB.

In 2024, companies like Vico Therapeutics raised $60 million in Series B funding. Venture firms LSP and Forbion actively invest alongside international backers. Companies like EV Biotech exemplify how government-backed funding combined with private venture capital enables scalable platform technologies for sustainable biomanufacturing. Linda Dijkshoorn, EV Biotech's Founder and CCO, shares how non-dilutive subsidies provided "playing money" in the riskiest early phase letting her learn entrepreneurship, refine the technology, and validate with customers while retaining ownership. This public bridge de-risked their science for investors, though she notes Dutch schemes' heavy bureaucracy demands lean operations and smart private partnerships for true scaling. Beyond funding, broader ecosystem advantages accelerate growth.

Strategic advantages include a central location for 450 million consumers, a skilled workforce, top universities, R&D tax incentives, IP protection, and logistics infrastructure. This ecosystem positions the Netherlands for sustained biotech growth aligned with its 2040 vision. 

The combination of substantial government commitment, active private investment, regulatory expertise through the EMA, and a comprehensive innovation ecosystem positions the Netherlands as one of Europe's most attractive destinations for biomolecular and cell technology ventures. The government's ambitious 2040 vision to establish the Netherlands as a future global leader in biotechnology, backed by concrete funding commitments and regulatory reforms, signals continued strong support for industry growth and development. These advantages create abundant career opportunities.